Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$101.93 -1.0%	$109.79	$81.20 ▼ $131.49	$24.76B	1.23	773,426 shs	907,273 shs
GRFS Grifols	$9.87 +0.7%	$9.86	$6.19 ▼ $11.14	$6.74B	0.56	984,975 shs	755,233 shs
INSM Insmed	$134.97 +0.3%	$110.06	$60.40 ▼ $136.90	$28.44B	0.95	3.09 million shs	1.76 million shs
TEVA Teva Pharmaceutical Industries	$18.03 -0.1%	$16.83	$12.47 ▼ $22.80	$20.70B	0.62	11.98 million shs	7.82 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	-1.05%	-7.98%	-8.57%	+6.50%	+15.57%
GRFS Grifols	+0.71%	-2.08%	-6.00%	+19.20%	+9.67%
INSM Insmed	+0.33%	+1.79%	+28.54%	+92.90%	+76.36%
TEVA Teva Pharmaceutical Industries	-0.28%	-4.08%	+9.21%	+7.48%	-2.93%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BNTX BioNTech	3.0713 of 5 stars	4.4	2.0	0.0	0.0	4.1	0.8	0.0
GRFS Grifols	3.6265 of 5 stars	1.3	3.0	2.5	0.0	3.0	0.0	5.0
INSM Insmed	3.797 of 5 stars	2.5	4.0	0.0	4.3	2.8	0.8	0.6
TEVA Teva Pharmaceutical Industries	3.3457 of 5 stars	3.6	4.0	0.0	0.0	3.5	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTX BioNTech	2.76	Moderate Buy	$135.80	33.23% Upside
GRFS Grifols	2.60	Moderate Buy	$10.30	4.36% Upside
INSM Insmed	2.94	Moderate Buy	$132.57	-1.78% Downside
TEVA Teva Pharmaceutical Industries	3.25	Buy	$24.71	37.11% Upside

Current Analyst Ratings Breakdown

Latest GRFS, INSM, BNTX, and TEVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	INSM Insmed	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$126.00 ➝ $144.00
8/20/2025	INSM Insmed	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$111.00 ➝ $135.00
8/20/2025	INSM Insmed	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
8/14/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$138.00 ➝ $136.00
8/14/2025	INSM Insmed	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$126.00 ➝ $139.00
8/14/2025	INSM Insmed	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$121.00 ➝ $145.00
8/13/2025	INSM Insmed	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$114.00 ➝ $142.00
8/13/2025	INSM Insmed	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$126.00
8/13/2025	INSM Insmed	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$129.00 ➝ $148.00
8/13/2025	INSM Insmed	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$130.00 ➝ $165.00
8/12/2025	INSM Insmed	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$130.00 ➝ $140.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTX BioNTech	$2.88B	8.51	N/A	N/A	$87.38 per share	1.17
GRFS Grifols	$7.81B	0.87	$0.94 per share	10.47	$12.55 per share	0.79
INSM Insmed	$363.71M	78.44	N/A	N/A	$5.91 per share	22.84
TEVA Teva Pharmaceutical Industries	$16.54B	1.25	$3.36 per share	5.37	$5.96 per share	3.02

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTX BioNTech	-$719.92M	-$1.60	N/A	N/A	N/A	-12.20%	-1.84%	-1.59%	11/3/2025 (Estimated)
GRFS Grifols	$169.80M	$1.17	8.44	9.40	0.33	N/A	N/A	N/A	11/5/2025 (Estimated)
INSM Insmed	-$913.77M	-$5.71	N/A	N/A	N/A	-259.82%	-195.37%	-49.49%	10/30/2025 (Estimated)
TEVA Teva Pharmaceutical Industries	-$1.64B	-$0.16	N/A	6.85	1.07	-0.95%	46.10%	7.18%	11/5/2025 (Estimated)

Latest GRFS, INSM, BNTX, and TEVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	INSM Insmed	-$1.30	-$1.70	-$0.40	-$1.70	$104.06 million	$107.42 million
8/4/2025	Q2 2025	BNTX BioNTech	-$1.41	-$1.60	-$0.19	-$1.82	$161.26 million	$306.46 million
7/30/2025	Q2 2025	TEVA Teva Pharmaceutical Industries	$0.64	$0.66	+$0.02	$0.24	$4.34 billion	$4.18 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTX BioNTech	$1.53	1.50%	N/A	N/A	N/A
GRFS Grifols	$0.14	1.42%	N/A	11.97%	N/A
INSM Insmed	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	N/A	N/A	N/A	N/A	N/A

Latest GRFS, INSM, BNTX, and TEVA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/30/2025	GRFS Grifols	special	$0.1404		8/12/2025	8/12/2025	8/20/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTX BioNTech	0.01	8.61	8.48
GRFS Grifols	1.20	2.64	0.95
INSM Insmed	0.45	6.68	6.33
TEVA Teva Pharmaceutical Industries	2.45	1.06	0.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTX BioNTech	15.52%
GRFS Grifols	N/A
INSM Insmed	N/A
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
BNTX BioNTech	19.20%
GRFS Grifols	0.19%
INSM Insmed	3.00%
TEVA Teva Pharmaceutical Industries	0.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTX BioNTech	6,772	240.40 million	194.24 million	Optionable
GRFS Grifols	23,822	687.55 million	686.25 million	Optionable
INSM Insmed	740	211.38 million	205.03 million	Optionable
TEVA Teva Pharmaceutical Industries	36,830	1.15 billion	1.14 billion	Optionable

GRFS, INSM, BNTX, and TEVA Headlines

Recent News About These Companies

APG Asset Management N.V. Decreases Stock Position in Teva Pharmaceutical Industries Ltd. $TEVA

2 hours ago | marketbeat.com

Analysts Set Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Target Price at $24.71

4 hours ago | americanbankingnews.com

Teva stock rises on launch of first generic weight loss GLP-1 drug

August 28 at 11:10 AM | in.investing.com

TEVA Trumpets Saxenda, Stocks Eke Higher

August 28 at 11:10 AM | baystreet.ca

Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss

August 28 at 11:10 AM | finance.yahoo.com

US FDA approves Teva Pharmaceuticals' generic obesity drug

August 28 at 9:17 AM | reuters.com

Raymond James Financial Inc. Decreases Stake in Teva Pharmaceutical Industries Ltd. $TEVA

August 28 at 4:00 AM | marketbeat.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Receives Consensus Recommendation of "Buy" from Analysts

August 28 at 3:26 AM | marketbeat.com

Teva's Pivot To (Innovative) Growth: Re-Rating Should Continue

August 28 at 2:01 AM | seekingalpha.com

How Investors May Respond To ACADIA Pharmaceuticals (ACAD) Hiring an Industry Veteran for Growth Strategy

August 27 at 8:09 AM | finance.yahoo.com

Quantbot Technologies LP Has $703,000 Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

August 27 at 4:12 AM | marketbeat.com

BI Asset Management Fondsmaeglerselskab A S Has $653,000 Stock Position in Teva Pharmaceutical Industries Ltd. $TEVA

August 26 at 4:24 AM | marketbeat.com

Piper Sandler Reiterates a Buy Rating on Teva Pharmaceutical Industries (TEVA)

August 25, 2025 | insidermonkey.com

Piper Sandler Reiterates a Buy Rating on Teva Pharmaceutical Industries (TEVA)

August 25, 2025 | finance.yahoo.com

Jump Financial LLC Has $20.37 Million Position in Teva Pharmaceutical Industries Ltd. $TEVA

August 25, 2025 | marketbeat.com

Russell Investments Group Ltd. Buys 61,330 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

August 25, 2025 | marketbeat.com

Charles Schwab Investment Management Inc. Buys 296,012 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

August 24, 2025 | marketbeat.com

Atika Capital Management LLC Invests $6.72 Million in Teva Pharmaceutical Industries Ltd. $TEVA

August 23, 2025 | marketbeat.com

Teva Pharmaceutical: Tariff Relief Clears The Way For Reinvention

August 22, 2025 | seekingalpha.com

Banco BTG Pactual S.A. Has $571,000 Position in Teva Pharmaceutical Industries Ltd. $TEVA

August 22, 2025 | marketbeat.com

Northwest & Ethical Investments L.P. Has $548,000 Stock Position in Teva Pharmaceutical Industries Ltd. $TEVA

August 22, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRFS, INSM, BNTX, and TEVA Company Descriptions

BioNTech NASDAQ:BNTX

$101.93 -1.08 (-1.05%)

Closing price 08/28/2025 04:00 PM Eastern

Extended Trading

$102.30 +0.37 (+0.36%)

As of 06:14 AM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Grifols NASDAQ:GRFS

$9.87 +0.07 (+0.71%)

Closing price 08/28/2025 04:00 PM Eastern

Extended Trading

$9.86 -0.01 (-0.10%)

As of 08/28/2025 04:04 PM Eastern

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Insmed NASDAQ:INSM

$134.97 +0.44 (+0.33%)

Closing price 08/28/2025 04:00 PM Eastern

Extended Trading

$134.90 -0.07 (-0.05%)

As of 06:01 AM Eastern

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Teva Pharmaceutical Industries NYSE:TEVA

$18.02 -0.03 (-0.14%)

Closing price 08/28/2025 03:59 PM Eastern

Extended Trading

$18.03 +0.01 (+0.03%)

As of 06:24 AM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time